[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-induced-neuropathic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-induced-neuropathic-pain":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100581287","phase-2-efficacy-and-safety-study-of-halneuron-in-the-treatment-of-chemotherapy-induced-neuropathic-pain-100581287",false,"NCT06848348","Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain","A Randomized, Double-Blind, Placebo Controlled, Multicenter Study With Optional Open-Label Extension to Evaluate the Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain","Inclusion Criteria:\n\n* Male or female patients aged ≥18 years.\n* Neuropathic pain has been present and is attributed to platinum and\u002For taxane chemotherapy.\n* Patient has received a cancer chemotherapy regimen that included taxanes and\u002For platinum and has no active or discernible disease progression.\n\nExclusion Criteria:\n\n* Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy.\n* Patients who have received HAL at any time prior to screening.","ALL","18 Years",{"count":19,"type":20},240,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.",[26,27,28],"Chemotherapy Induced Neuropathic Pain","Chemotherapy Induced Pain Neuropathy","Chemotherapy Induced Pain",[30,31,32,33,34,35,36,37,38,39,40,41],"Chemotherapy","Pain","Neuropathy","Cancer","CIPN","CINP","Chemotherapy Induced","Neuropathic Pain","Breast Cancer","Colorectal Cancer","Cancer Pain","Peripheral Neuropathy","RECRUITING","2026-05-27",{"date":45,"type":46},"2026-05-29","ACTUAL",{"date":48,"type":46},"2025-02-21",{"date":50,"type":20},"2026-08",{"name":52,"class":53},"Dogwood Therapeutics Inc.","INDUSTRY",25,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100632275","prospective-exploratory-study-of-a-multiomic-blood-biomarker-panel-to-predict-chemotherapy-induced-peripheral-neuropathy-cipn-100632275","NCT07511569","Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)","PRECISE1","Inclusion Criteria:\n\n* Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study\n* Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more\n* Age \\> 18 years\n* Life expectancy \\> 3 months\n* Patient affiliated with or entitled to social security\n\nExclusion Criteria:\n\n* Patients already suffering from neuropathy or chronic neurogenic pain\n* Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes)\n* Patients who have already received neurotoxic cancer treatment including those in clinical trials\n* Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule)\n* Patients receiving immunotherapy",{"count":63,"type":20},192,"OBSERVATIONAL","The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.",[26,67,68,69],"Neuropathy Toxic","Taxane-induced Peripheral Neuropathy","Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","NOT_YET_RECRUITING","2026-04-07",{"date":73,"type":46},"2026-04-13",{"date":75,"type":20},"2027-01-04",{"date":77,"type":20},"2029-06-04",{"name":79,"class":80},"Centre Hospitalier de Bligny","OTHER"]